Literature DB >> 8723888

Disposition of transdermally administered fentanyl in dogs.

A E Kyles1, M Papich, E M Hardie.   

Abstract

OBJECTIVE: To evaluate the disposition of fentanyl after i.v. and transdermal administrations. The hypothesis was that transdermal administration of fentanyl would result in a measurable plasma opioid concentration.
DESIGN: Each dog received 2 treatments in a randomized, crossover design. ANIMALS: 6 clinically normal Beagles. PROCEDURE: 2 treatments consisting of i.v. fentanyl (50 micrograms/kg of body weight) and transdermal fentanyl (50 micrograms/h) administrations. Plasma fentanyl concentrations were measured at fixed times, and pharmacokinetic values were calculated.
RESULTS: Intravenous pharmacokinetics of fentanyl was similar to those previously described in dogs and provided the distribution and clearance data necessary to calculate the rate of absorption of the transdermally administered opioid. The transdermal fentanyl patch produced average steady-state concentrations of 1.6 ng/ml. The actual rate of delivery of transdermal fentanyl was 35.7 (range, 13.7 to 49.8) micrograms/h, which represented 71.48% (range, 27.45 to 99.56%) of the theoretical rate of delivery. The mean elimination half-life of fentanyl after patch removal was 1.39 hours.
CONCLUSIONS: Transdermally administered fentanyl resulted in fairly constant plasma concentrations, in the range generally considered to be analgesic, from 24 to 72 hours after application of the patch. The rate of drug delivery was less than expected, and there was substantial individual variation. CLINICAL RELEVANCE: Transdermally administered fentanyl has the potential to be a clinically useful analgesic regimen in dogs, and further evaluation of its analgesic actions and potential side effects warranted

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8723888

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  6 in total

Review 1.  Drug compounding for veterinary patients.

Authors:  Mark G Papich
Journal:  AAPS J       Date:  2005-09-22       Impact factor: 4.009

2.  Pharmacokinetics of ammonium sulfate gradient loaded liposome-encapsulated oxymorphone and hydromorphone in healthy dogs.

Authors:  Lesley J Smith; Butch K Kukanich; Lisa A Krugner-Higby; Brynn H Schmidt; Timothy D Heath
Journal:  Vet Anaesth Analg       Date:  2013-04-20       Impact factor: 1.648

3.  Long-Lasting Analgesia With Transdermal Fentanyl: A New Approach in Rat Neonatal Research.

Authors:  Isabelle Dutriez-Casteloot; Virginie Emmanuelli; Jean-François Wiart; Annabelle Tavernier; Capucine Besengez; Laurent Storme; Véronique Houfflin-Debarge
Journal:  Front Pharmacol       Date:  2022-03-17       Impact factor: 5.810

4.  Case Report: Intoxication in a Pig (Sus Scrofa Domesticus) After Transdermal Fentanyl Patch Ingestion.

Authors:  Jerneja Sredenšek; Maša Bošnjak; Urša Lampreht Tratar; Tina Kosjek; Maja Cemazar; Mojca Kržan; Alenka Seliškar
Journal:  Front Vet Sci       Date:  2020-11-24

5.  The safety and effectiveness of a long-acting transdermal fentanyl solution compared with oxymorphone for the control of postoperative pain in dogs: a randomized, multicentered clinical study.

Authors:  S A Martinez; M G Wilson; D D Linton; G C Newbound; K J Freise; T-L Lin; T P Clark
Journal:  J Vet Pharmacol Ther       Date:  2013-12-18       Impact factor: 1.786

6.  Fentanyl patch versus tramadol for the control of postoperative pain in canine ovariectomy and mastectomy.

Authors:  Vincenzo Cicirelli; Giulio G Aiudi; Daniela Mrenoshki; Giovanni M Lacalandra
Journal:  Vet Med Sci       Date:  2021-12-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.